THU0299 B Cell Compartment and Pharmacodynamics of Belimumab in Systemic Lupus Erythematosus: Early...
THU0299 B Cell Compartment and Pharmacodynamics of Belimumab in Systemic Lupus Erythematosus: Early Clinical Efficacy by Depletion of CD27- and Increase of CD27+ B Cells
About this item
Full title
Author / Creator
Quartuccio, L. , De Marchi, G. , Rossi, F.M. , Zuliani, F. , Bond, M. , Picco, L. , Masolini, P. , Rizzolio, F. and De Vita, S.
Publisher
Kidlington: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
BackgroundBelimumab, a human anti-BAFF monoclonal antibody that inhibits soluble BAFF, is effective in systemic lupus erythematosus (SLE), and leads to a partial B cell depletion. However, which subset of B cells may be the main therapeutic target of belimumab in SLE is still unclear.ObjectivesPrimary objective of this study was to evaluate the eff...
Alternative Titles
Full title
THU0299 B Cell Compartment and Pharmacodynamics of Belimumab in Systemic Lupus Erythematosus: Early Clinical Efficacy by Depletion of CD27- and Increase of CD27+ B Cells
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2441493494
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2441493494
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2016-eular.4659
